Progress in fibrinolysis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This review deals with aspects of fibrinolysis in which significant developments have taken place in the last few years. The structural changes of plasminogen during its activation are now identified precisely; the recent description of a thrombotic tendency in a kindred characterized by a defect of this protein emphasizes its important role in the homeostatic balance. Several activators of plasminogen are now identified; some of them, such as tissue and vascular activators, appear to have an important role in physiology and pathology. The recent characterizations of the α-antiplasmin and of antiactivators have widened our understanding of the inhibitors of fibrinolysis: a defect of the plasmin inhibitor seems to be associated with an hacmorrhagic tendency, whereas high antiactivator levels were encountered in thrombotic conditions. The clinical use of fibrinolytic agents appears to be promising in conditions such as recurrent deep vein thrombosis and in the post-phlebitic syndrome. Thrombolytic therapy with urokinase or streptokinase appears to have elective indications in patients with acute deep vein thrombosis and massive life-threatening pulmonary embolism.

Original languageEnglish
Pages (from-to)223-233
Number of pages11
JournalLa Ricerca in Clinica e in Laboratorio
Volume9
Issue number3
DOIs
Publication statusPublished - Jul 1979

Fingerprint

Antifibrinolytic Agents
Fibrinolysis
Venous Thrombosis
Defects
Streptokinase
Fibrinolytic Agents
Plasminogen Activators
Plasminogen
Thrombolytic Therapy
Physiology
Urokinase-Type Plasminogen Activator
Pathology
Pulmonary Embolism
Blood Vessels
Chemical activation
Tissue
Proteins

Keywords

  • Fibrinolysis
  • Fibrinolytic agents
  • Plasminogen
  • Thrombolysis
  • Thrombolytic agents

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Progress in fibrinolysis. / Mannucci, Pier Mannuccio.

In: La Ricerca in Clinica e in Laboratorio, Vol. 9, No. 3, 07.1979, p. 223-233.

Research output: Contribution to journalArticle

@article{b3efb80723f54dcc92610936ad4a3f48,
title = "Progress in fibrinolysis",
abstract = "This review deals with aspects of fibrinolysis in which significant developments have taken place in the last few years. The structural changes of plasminogen during its activation are now identified precisely; the recent description of a thrombotic tendency in a kindred characterized by a defect of this protein emphasizes its important role in the homeostatic balance. Several activators of plasminogen are now identified; some of them, such as tissue and vascular activators, appear to have an important role in physiology and pathology. The recent characterizations of the α-antiplasmin and of antiactivators have widened our understanding of the inhibitors of fibrinolysis: a defect of the plasmin inhibitor seems to be associated with an hacmorrhagic tendency, whereas high antiactivator levels were encountered in thrombotic conditions. The clinical use of fibrinolytic agents appears to be promising in conditions such as recurrent deep vein thrombosis and in the post-phlebitic syndrome. Thrombolytic therapy with urokinase or streptokinase appears to have elective indications in patients with acute deep vein thrombosis and massive life-threatening pulmonary embolism.",
keywords = "Fibrinolysis, Fibrinolytic agents, Plasminogen, Thrombolysis, Thrombolytic agents",
author = "Mannucci, {Pier Mannuccio}",
year = "1979",
month = "7",
doi = "10.1007/BF02932174",
language = "English",
volume = "9",
pages = "223--233",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Progress in fibrinolysis

AU - Mannucci, Pier Mannuccio

PY - 1979/7

Y1 - 1979/7

N2 - This review deals with aspects of fibrinolysis in which significant developments have taken place in the last few years. The structural changes of plasminogen during its activation are now identified precisely; the recent description of a thrombotic tendency in a kindred characterized by a defect of this protein emphasizes its important role in the homeostatic balance. Several activators of plasminogen are now identified; some of them, such as tissue and vascular activators, appear to have an important role in physiology and pathology. The recent characterizations of the α-antiplasmin and of antiactivators have widened our understanding of the inhibitors of fibrinolysis: a defect of the plasmin inhibitor seems to be associated with an hacmorrhagic tendency, whereas high antiactivator levels were encountered in thrombotic conditions. The clinical use of fibrinolytic agents appears to be promising in conditions such as recurrent deep vein thrombosis and in the post-phlebitic syndrome. Thrombolytic therapy with urokinase or streptokinase appears to have elective indications in patients with acute deep vein thrombosis and massive life-threatening pulmonary embolism.

AB - This review deals with aspects of fibrinolysis in which significant developments have taken place in the last few years. The structural changes of plasminogen during its activation are now identified precisely; the recent description of a thrombotic tendency in a kindred characterized by a defect of this protein emphasizes its important role in the homeostatic balance. Several activators of plasminogen are now identified; some of them, such as tissue and vascular activators, appear to have an important role in physiology and pathology. The recent characterizations of the α-antiplasmin and of antiactivators have widened our understanding of the inhibitors of fibrinolysis: a defect of the plasmin inhibitor seems to be associated with an hacmorrhagic tendency, whereas high antiactivator levels were encountered in thrombotic conditions. The clinical use of fibrinolytic agents appears to be promising in conditions such as recurrent deep vein thrombosis and in the post-phlebitic syndrome. Thrombolytic therapy with urokinase or streptokinase appears to have elective indications in patients with acute deep vein thrombosis and massive life-threatening pulmonary embolism.

KW - Fibrinolysis

KW - Fibrinolytic agents

KW - Plasminogen

KW - Thrombolysis

KW - Thrombolytic agents

UR - http://www.scopus.com/inward/record.url?scp=0018488441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018488441&partnerID=8YFLogxK

U2 - 10.1007/BF02932174

DO - 10.1007/BF02932174

M3 - Article

VL - 9

SP - 223

EP - 233

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 3

ER -